Quest Diagnostics Hits New 52-Week High of $213.50, Up 49.79%

Quest Diagnostics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 213.50 on February 27, 2026. This achievement underscores the company's strong performance in the market, particularly as it has delivered a remarkable 49.79% return over the past year, significantly outperforming the S&P 500, which has seen a return of 17.36% during the same period. As a mid-cap company with a market capitalization of USD 32,839 million, Quest Diagnostics operates within the miscellaneous industry. The stock's price-to-earnings (P/E) ratio stands at 29.00, reflecting its valuation in relation to its earnings. Additionally, the company boasts a robust dividend yield of 28.15%, indicating a strong return for shareholders. With a debt-to-equity ratio of 0.76 and a return on equity of 15.73%, Quest Diagnostics demonstrates a solid financial position. The price-to-book ratio of 4.58 further highlights its valuation metrics. Overall, the recent price movement and performance indicators suggest a strong standing in the market for Quest Diagnostics.